(Q38183569)

30 August 2017

The immune system and response to HER2-targeted treatment in breast cancer (English)

1 reference

30 August 2017

1 reference

2

Luca Gianni

1 reference

30 August 2017

Giampaolo Bianchini

1

1 reference

30 August 2017

1 February 2014

1 reference

Lancet Oncology Commission

30 August 2017

1 reference

30 August 2017

15

1 reference

30 August 2017

2

1 reference

30 August 2017

e58-68

1 reference

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Oncogenic stress sensed by the immune system: role of natural killer cell receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Adaptive immunity maintains occult cancer in an equilibrium state

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Translational medicine: Cancer lessons from mice to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immunological aspects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immunogenic death of colon cancer cells treated with oxaliplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immune parameters affecting the efficacy of chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Fcgamma receptors as regulators of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

The IgG Fc receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Effect of FCGR2A and FCGR3A variants on CLL outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Innate or adaptive immunity? The example of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cutting edge: tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immune complex-mediated antigen presentation induces tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Effector and regulatory events during natural killer-dendritic cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

1 reference

7 January 2021

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Immunostimulatory monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Combining immunotherapy and targeted therapies in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Cancer immunotherapy comes of age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970477-7

7 January 2021

10.1016/S1470-2045(13)70477-7

Identifiers

DOI

1 reference

release_aqoaqpsi6vdjjd4c3kebt6igpq

30 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aqoaqpsi6vdjjd4c3kebt6igpq

24 November 2022

mapped directly with Wikidata item

PubMed ID

24480556

1 reference

PubMed ID

24480556